In randomized controlled trials, there are two treatment solutions now regarded the standard of care in Guillain-Barré syndrome (GBS). These contain either intravenous immunoglobulin (IVIG) or plasma exchange. IVIG is believed to act by its immune-modulating motion; nevertheless, the exact mechanism continues to be for being elucidated. IVIG is s